Table 1.
Demographics of participants.
| Ocrelizumab patients after 2nd vaccine | Ocrelizumab patients after 3rd vaccination | Fingolimod patients after 2nd vaccine | Fingolimod patients after 3rd vaccine | Healthy controls after 2nd vaccine | Healthy controls after 3rd vaccine | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 33) | T-cell (n = 10) | All (n = 22) | T-cell (n = 9) | All (n = 7) | T-cell (n = 6) | All (n = 21) | T-cell (n = 10) | All (n = 29) | T-cell (n = 8) | All (n = 7) | T-cell (n = 5) | |
| Age, median [IQR] years | 54.9 [12.3] | 47.2 [12.7] | 54.5 [13.0] | 53.9 [9] | 51.1 [4.6] | 49.9 [4.2] | 51.8 [9.9] | 50.5 [11.25] | 36.6 [25.4] | 52.0 [19.5] | 27.8 [15.4] | 27.8 [5.4] |
| Female, n (%) | 24 (72.7%) | 7 (70%) | 16 (72.7%) | 6 (66.7%) | 5 (71.4%) | 4 (66.7%) | 16 (76.2%) | 8 (80%) | 13 (44.8%) | 5 (62.5%) | 6 (85.7%) | 4 (80%) |
| EDSS, median [IQR] | 1.5 [4.5] | 2.5 [3.9] | 2.5 [1.9] | 3 [2] | 1.5 [1] | 1.25 [0.5] | 1.5 [1] | 1.75 [0.5] | NA | NA | NA | NA |
| Time on DMT prior to first vaccine, median [IQR] years | 2.07 [1.8] | 2.54 [1.8] | 2.47 [1.1] | 3.01 [0.7] | 8.24 [1.6] | 7.79 [1.4] | 8.0 [3.8] | 5.24 [4.2] | NA | NA | NA | NA |
| Type of MS | ||||||||||||
| RRMS | 22 | 6 | 17 | 6 | 6 | 6 | 21 | 10 | NA | NA | NA | NA |
| SPMS | 8 | 3 | 4 | 2 | 1 | 0 | 0 | 0 | NA | NA | NA | NA |
| PPMS | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | NA | NA | NA | NA |
| Time sample after 2nd dose vaccine, median [IQR] days | 83 [24] | 89.5 [19] | NA | NA | 95 [19] | 91.5 [25] | NA | NA | 76 [24] | 78.5 [17.5] | NA | NA |
| Time sample after 3rd dose vaccine, median [IQR] days | NA | NA | 62 [39.8] | 83 [17] | NA | NA | 62 [4] | 63 [5.8] | NA | NA | 70 [7] | 64 [6] |
| Time between 2nd and 3rd dose vaccine, median [IQR] days | NA | NA | 115.5 [32.5] | 104 [48] | NA | NA | 132 [39] | 127 [34.25] | NA | NA | 275 [7.5] | 276 [2] |
| Time between ocrelizumab infusion and 1st vaccine, median [IQR] days | 90 [42] | 92 [17] | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Time between ocrelizumab infusion and 3rd vaccine, median [IQR] days | NA | NA | 88 [43] | 84 [88] | NA | NA | NA | NA | NA | NA | NA | NA |
| Vaccine type, primary | ||||||||||||
| mRNA-1273 | 9 | 3 | 7 | 5 | 1 | 1 | 8 | 4 | 10 | 2 | 5 | 3 |
| BNT162b2 | 24 | 7 | 15 | 4 | 6 | 5 | 13 | 6 | 19 | 6 | 2 | 2 |
| Vaccine type, 3rd dose | ||||||||||||
| mRNA-1273 a | NA | NA | 6 | 3 | NA | NA | 8 | 4 | NA | NA | 5 | 3 |
| BNT162b2 | NA | NA | 16 | 6 | NA | NA | 13 | 6 | NA | NA | 2 | 2 |
a
Of the 14 mRNA-1273 3rd doses, 9 patients received 0.5 mL (100 mcg) the other 5 patients had unknown quantities.
NA: not applicable; RRMS: relapsing remitting MS; SPMS: secondary progressive MS; PPMS: primary progressive MS.